• 1
    Hewitt M, Greenfield SE. From Cancer Patient to Cancer Survivors. Lost in Translation. Washington, DC: National Academies Press; 2005.
  • 2
    Ahles T, Saykin A. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007; 7: 192-201.
  • 3
    Correa DD, Ahles TA. Cognitive adverse effects of chemotherapy in breast cancer patients. Curr Opin Support Palliat Care. 2007; 1: 57-62.
  • 4
    Jim HSL, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009; 115: 1776-1783.
  • 5
    Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatment for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003; 9: 967-982.
  • 6
    Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips K-A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cognition. 2005; 59: 60-70.
  • 7
    Minisini A, Atalay G, Bottomley A, Puglisi F, Piccart M, Biganzoli L. What is the effect of systemic anticancer treatment on cognitive function? The Lancet Oncology. 2004; 5: 273-282.
  • 8
    Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004; 22: 2233-2239.
  • 9
    Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009; 15: 951-962.
  • 10
    Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003; 12: 612-619.
  • 11
    Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997; 278: 1349-1356.
  • 12
    Small BJ, Rosnick CB, Fratiglioni L, Bäckman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging. 2004; 19: 592-600.
  • 13
    Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol Aging. 2009 Mar 12. [Epub ahead of print].
  • 14
    Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: dopamine, COMT, and BDNF. Genes Brain and Behavior. 2006; 5: 311-328.
  • 15
    Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cog Sci. 2004; 8: 325-335.
  • 16
    Nagel IE, Chicherio C, Li SC, et al. Human aging magnifies genetic effects on executive functioning and working memory. Front Hum Neurosci. 2008; 2: 1.
  • 17
    Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007; 25: 3866-3870.
  • 18
    Silverman DHS, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007; 103: 303-311.
  • 19
    Andrykowski MA, Burris JL, Walsh E, Small BJ, Jacobsen PB. Attitudes toward information about genetic risk for cognitive impairment after cancer chemotherapy: breast cancer survivors compared with healthy controls. J Clin Oncol. 2010; 28: 3442-3447.
  • 20
    Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005; 104: 2499-2507.
  • 21
    Nelson HE. The National Adult Reading Test (NART): Test Manual. Windsor, Berks, UK: NFER-Nelson; 1982.
  • 22
    Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test: Adult Version. San Antonio, TX: Psychological Corporation; 1987.
  • 23
    Wechsler D. Weschler Memory Scale-III Manual. San Antonio, TX: Psychological Corporation; 1997.
  • 24
    Wechsler D. WAIS-III Administration and Scoring Manual. San Antonio, TX: Psychological Corporation; 1997.
  • 25
    D'Elia LF, Satz P, Uchiyama CL, White T. Color Trails Test. Odessa, FL: Psychological Assessment Resources; 1996.
  • 26
    Benton A, Hamsher K. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates; 1989.
  • 27
    Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press; 1993.
  • 28
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer. 2004; 100: 2292-2299.
  • 29
    Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FSAM. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006; 98: 1742-1745.
  • 30
    Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002; 13: 1387-1397.
  • 31
    Schagen SB, van Dam FSAM, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999; 85: 640-650.
  • 32
    Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979; 6: 65-70.
  • 33
    Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010; 116: 3348-3356.
  • 34
    Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006; 24: 1633-1642.
  • 35
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485-493.
  • 36
    Goldberg TE, Egan MF, Gscheidle T, et al. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry. 2003; 60: 889-896.
  • 37
    Barnett JH, Scoriels L, Munafò MR. Meta-analysis of the cognitive effects of the Catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry. 2008; 64: 137-144.
  • 38
    Guttmacher AE, Collins FS. Genetic medicine–a primer. New Engl J Med. 2002; 347: 1512-1520.
  • 39
    Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010; 363: 301-304.